BioSpace News Archive

Novamind’s subsidiary Cedar Psychiatry has administered over 5,000 ketamine treatments and over 2,000 Spravato™ treatments

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, announced the pricing of its previously announced underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock.

PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced the publication of a new scientific paper titled, “Bovine colostrum: Its constituents and uses” in the peer-reviewed journal Nutrients.

Hyperquake introduces The Neuropulse Program™ to track emotional engagement that can be used to enhance a broad range of business-building creative content, including consumer product development, marketing, communications, digital or in-person experiences, and other applications to optimize engagement and influence purchase behavior.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2020 on Thursday, February 11, 2021, before the U.S. financial markets open.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Helius.

Healthcare Technology Report award recognizes outstanding contributions by SVP Suzon Lommel to advance innovative technologies that can transform patient outcomes

Dominion Aesthetic Technologies, developers of EON - the touchless, intelligent body contouring device - has successfully closed Series B financing, raising a total of $23.7 million.

Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe.

Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the commercial availability of its viral transport medium (VTM) to support Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease.